Dr. Burdelya earned her PhD in Experimental Oncology at the Blokhin Cancer Research Center in Moscow, Russia, and completed her postdoctoral research in Tumor Immunology at the Moffitt Cancer Center and Research Institute, Tampa, Florida. Before joining Roswell Park Comprehensive Cancer Center, she worked as a Research Associate in the Department of Molecular Genetics at The Cleveland Clinic Foundation, Cleveland, Ohio.
Dr. Burdelya is an active member of the American Association for Cancer Research and the Radiation Research Society. She is the author of over 20 peer-reviewed articles and numerous abstracts.
Currently, Dr. Burdelya’s research program is focused on the development and application of immune response modulators which act through TLR5 signaling for the prevention of normal tissue injury and reduction of adverse side effects induced by radiation and chemotherapeutic agents. Associated pre-clinical studies include the use of TLR5 agonists for anticancer therapy both alone or in combination with existing anti-cancer therapies.
- Development of a new approach to anti-cancer therapy based on the activation of TLR5 signaling for the prevention of normal tissue injury and reduction of adverse side effects as may be induced by local irradiation or chemotherapeutic agents with dose-limiting toxicities.
- Investigation of the mechanisms underlying the protection provided by TLR5 agonists.
- Development of TLR5 agonists as potential anticancer therapeutic agents.
- Development of a potent immunostimulatory anticancer therapy by the rational combination of TLR5 agonistic agents with existing anticancer therapies.
Burdelya LG, Feinstein E, Didonato JA, Osterman AL, Fort FL, Kurnasov OV, Gupta D, Gleiberman AS, Strom E, Tallant TC, Krivokrysenko VI, Gudkov AV.An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science (New York, N.Y.) 2008; 320(5873):226-230
Logunov DY, Ginzburg AL, Naroditsky BS, Burdelya LG, Tararova ND, Gurova KV, Rakovskaya IV, Shmarov MM, Zubkova OV, Scheblyakov DV, Gudkov AV.Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation. Oncogene 2008;27(33):4521-4531
Burdelya LG, Gleiberman AS, Toshkov I, Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P, Bellnier D, Krivokrysenko VI, Feinstein E, Gudkov AV.Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy.International journal of radiation oncology, biology, physics 2012; 83(1):228-234
Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proceedings of the National Academy of Sciences of the United States of America 2012; 109(33):13314-13318